PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.
暂无分享，去创建一个
Jeffrey A Jones | J. Byrd | F. Awan | J. Blachly | L. Andritsos | Xiaoli Zhang | R. Lapalombella | A. Lehman | Y. Zhong | K. Williams | J. Woyach | K. Maddocks | D. El-Gamal | Chia-Hsien Wu | Matthew Cannon | Taylor D. LaFollette | E. Williams | Ching S. Chen | Xiaoli Zhang